【7月8日远大医药高开5.5%，易甘泰获FDA提前批准新增适应症】7月8日，远大医药高开5.5%，报9.78港元。消息显示，远大医药易甘泰近日获FDA提前正式批准新增HCC适应症，成全球唯一FDA批准双适应症SIRT产品。 昨晚，远大医药公告，基于钇[90Y]微球注射液DOORwaY90临床试验突破性中期数据达预设共同主要终点，FDA提前正式批准该产品新增治疗不可切除肝细胞癌(HCC)适应症，且未...
Source Link【7月8日远大医药高开5.5%，易甘泰获FDA提前批准新增适应症】7月8日，远大医药高开5.5%，报9.78港元。消息显示，远大医药易甘泰近日获FDA提前正式批准新增HCC适应症，成全球唯一FDA批准双适应症SIRT产品。 昨晚，远大医药公告，基于钇[90Y]微球注射液DOORwaY90临床试验突破性中期数据达预设共同主要终点，FDA提前正式批准该产品新增治疗不可切除肝细胞癌(HCC)适应症，且未...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.